A5027490214- Pharmaceutical studies and practices
- Drug-Induced Hepatotoxicity and Protection
- Antibiotics Pharmacokinetics and Efficacy
- Liver Disease and Transplantation
- Anesthesia and Sedative Agents
- Biosensors and Analytical Detection
- Antimicrobial Resistance in Staphylococcus
- Liver Disease Diagnosis and Treatment
Centre for Human Drug Research
2023-2024
Leiden University
2023-2024
Contradictory pharmacokinetic (PK) results have been observed between obese adults and adolescents, with absolute clearance (CL) reported to be either unaltered, lower, or higher in adolescents compared adults. This study investigates the PK of vancomycin who are overweight obese.Data from 125 (aged 10-18 years, weight 28.3-188 kg) 81 29-88 66.7-143 were analysed using population modelling. In addition age, sex, renal function estimates, regular descriptors, we evaluated standard...
The latest vancomycin guideline recommends area under the curve (AUC)-targeted dosing and monitoring for efficacy safety. However, guidelines AUC-targeted starting in patients with obesity and/or renal insufficiency are currently lacking. This study quantifies pharmacokinetics (PK) of this population provides recommendations.
Drug clearance in obese subjects varies widely among different drugs and across with severity of obesity. This study investigates correlations between plasma (CLp) drug- patient-related characteristics subjects, evaluates the systematic accuracy common weight-based dosing methods. A physiologically-based pharmacokinetic (PBPK) modeling approach that uses recent information on obesity-related changes physiology was used to simulate CLp for a normal-weight subject (body mass index [BMI] = 20)...